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Multinuclear ruthenium(II) complexes as
anticancer agents
Anil K. Gorle,a Alaina J. Ammit,b Lynne Wallace,*a F. Richard Keene*cde and
J. Grant Collins*a
A series of dinuclear ruthenium(II) complexes that contain labile chlorido ligands, [{Ru(tpy)Cl}2{m-bbn}]
2+
{designated Cl-Rubbn; tpy = 2,20:60,200-terpyridine, bbn = bis[4(40-methyl-2,20-bipyridyl)]-1,n-alkane
(n = 7, 10, 12, 14 or 16)} and derivatives containing nitro substituents on the tpy ligand and/or secondary
amines within the bbn linking chain have been synthesised and their potential as anticancer agents
examined. Some of the Cl-Rubbn species showed good anticancer activity against MCF-7 and MDA-MB-
231 breast cancer cell lines, with the Cl-Rubb12 complex being four-times more active than cisplatin.
Inclusion of nitro substituents on the tpy ligands of Cl-Rubb12 resulted in significantly decreased
anticancer activity. The incorporation of amine groups into the linking ligand did not increase the
anticancer activity of the Cl-Rubbn complexes. The Cl-Rubbn complexes and those containing amine
groups in the linking chain aquated at approximately the same rate, with 50% aquation within 120 minutes.
By comparison, the complexes containing nitro substituents on the tpy ligand aquated extremely slowly,
with 60% of the chlorido complex remaining 24 hours after they were dissolved in water. Cyclic
voltammetry with the model mononuclear complex [Ru{(NO2)3tpy}(Me2bpy)Cl]
+ {(NO2)3tpy = 4,40,400-
trinitro-2,20:60,200-terpyridine} showed that the nitro substituents exerted a strong effect on the ruthenium
centre, with the anodic peak corresponding to the Ru(III/II) couple shifted positively by 300 mV compared
to that from the non-nitrated parent complex [Ru(tpy)(Me2bpy)Cl]
+. 1H NMR studies of the reaction of the
Cl-Rubbn complexes with GMP indicated that the ruthenium complexes covalently bound the nucleotide
slowly, with 33% bound in 24 hours. However, the results of this study suggest that the cytotoxicity of the
dinuclear ruthenium complexes is a combination of covalent and reversible binding with DNA.
Introduction
Although cisplatin has been in clinical use for over 30 years,
its toxicity and natural/acquired resistance to many cancers
has considerably limited its application.1 While some second-
generation platinum complexes are less toxic than cisplatin,
and others can partially overcome acquired resistance, there
has been little success in developing drugs that are active in
cancer cell lines resistant to cisplatin. Consequently, there has
been considerable interest in the development of ‘‘non-classical’’
platinum complexes – complexes that can bind DNA in a
different manner than cisplatin and its analogues.2–7
Multinuclear platinum complexes, where two or more plati-
num coordination units are linked by a variety of organic ligand
bridges, represent a genuinely new class of anticancer drug.2
While complexes with bi-functional platinum centres have
been reported, those containing mono-functional coordinating
spheres on the terminal platinum atoms (e.g. BBR 3005,
see Fig. 1) gave the most encouraging results.8–11 Furthermore,
complexes bearing a cationic charge and hydrogen-bonding
capacity (e.g. amine groups or inert am(m)ineplatinum(II)
centres) in the linking ligand were shown to be the most active
in both cisplatin-sensitive and -resistant cell lines.12–20 The
trinuclear complex BBR 3464, [trans-{PtCl(NH3)2}2-{m-trans-
Pt(NH3)2(H2N(CH2)6NH2)2}]
4+, has undergone Phase II clinical
trials,21–23 while dinuclear complexes linked by spermidine
(BBR 3571, see Fig. 1) and spermine (BBR 3610 and BBR
3611) are cytotoxic at nanomolar concentrations.2
While the multinuclear platinum complexes are highly
cytotoxic, they are also highly toxic.13,23–26 Furthermore, upon
administration they bind thiol-containing plasma proteins in
the bloodstream, and are subsequently degraded to non-active
metabolites. Although BBR 3464 has been withdrawn from
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clinical trials, there has been recent interest in ‘‘transferring the
concept of multinuclearity to ruthenium complexes’’.27 Mendoza-
Ferri et al. synthesised a series of dinuclear ruthenium(II)–arene
compounds containing a bis(pyridinone)alkane linking ligand
that incorporated 3, 6 or 12 methylene groups in the alkane
chain.27 The ruthenium–arene complexes showed good activity in
a variety of cancer cell lines, with the activity increasing with the
length of the alkane linker, and were more active than a similar
mononuclear analogue. In addition, Yamada et al. synthesised
[{Ru(bpy)2Cl}2{m-BL}]
2+ complexes {where bpy = 2,20-bipyridine
and BL = 1,6-diaminohexane or 1,12-diaminododecane} and
examined their cytotoxicity.28 While the chlorido complexes
showed little activity, replacement of the chlorido ligand by DMSO
in the 1,12-diaminododecane-bridged complex resulted in good
activity against L1210 cells.
Corral et al. have recently demonstrated that the mono-
nuclear ruthenium(II) complexes [Ru(apy)(tpy)X]n+ (where apy =
azobis(2-pyridine), tpy = 2,20:60,200-terpyridine and X = a labile
ligand such as Cl or H2O) had good activity against a variety
of cancer cell lines, but were significantly less active than
cisplatin.29 In an attempt to increase the activity of mononuclear
[Ru(tpy)(L)(Cl)]+ complexes (where L = a non-labile bidentate
ligand), we previously synthesised the dinuclear ruthenium
complexes [{Ru(tpy)Cl}2{m-bbn}]
2+ {Cl-Rubbn, see Fig. 2; where
bbn = bis[4(40-methyl-2,20-bipyridyl)]-1, n-alkane, for n = 7, 10, 12,
and 14}.30 The Cl-Rubbn complexes showed good activity against
the highly sensitive L1210 cell line (IC50 E 5–10 mM) and were
ten-times more active than the corresponding mononuclear
complex [Ru(tpy)(Me2bpy)Cl]
+ {Me2bpy = 4,40-dimethyl-2,20-
bipyridine}.30 In this present study we sought to extend the
family of Cl-Rubbn dinuclear complexes by using a similar
approach to that of Farrell and co-workers for the multinuclear
platinum complexes.2,9–11 Consequently, we have synthesised
and examined the anticancer activities, rates of hydrolysis, and
binding ability to guanosine 50-monophosphate (GMP) of a
series of Cl-Rubbn complexes that contain cationic groups
(NH2
+) in the chain of the bbn linking ligand (Cl-RubbNn).
Fig. 1 Cisplatin, and the structure of a generic dinuclear platinum
complex (top right) with the linking ligands (Y) shown for BBR 3464, BBR
3005 and BBR 3571.
Fig. 2 Chlorido-containing dinuclear ruthenium(II) complexes, top Cl-Rubbn for X = H and Cl-RubbnNO2 for X = NO2, and bottom Cl-RubbNn for
X = H and Cl-RubbNnNO2 for X = NO2.
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Furthermore, in order to determine the effect of changes in
charge distribution (and hence, the rate of ligand exchange)
on the ruthenium(II) complexes, we have prepared several
Cl-Rubbn and Cl-RubbNn complexes that contain three electron-
withdrawing NO2 groups on the tpy ligands (Cl-RubbnNO2 and
Cl-RubbNnNO2).
Results
Synthesis
The synthesis of the mononuclear [Ru(tpy)(bpy)Cl]+ and the
dinuclear complexes [{Ru(tpy)Cl}2(m-bbn)]
2+ (Cl-Rubbn for n = 7,
10, 12, 14 and 16) have been previously reported.30,31 In this
study, we have extended the family of dinuclear complexes
through the synthesis of Cl-RubbnNO2, Cl-RubbNn, and
Cl-RubbNnNO2 complexes, as shown in Schemes 1–3. For the
Cl-RubbNn complexes, the procedure used for the synthesis of
the Cl-Rubbn complexes resulted in poor yield and purity for
the Cl-RubbNn complexes. To obtain satisfactory yields the
bbNn ligand was dissolved in ethanol–water and heated to
60 1C before the [Ru(tpy)Cl3] was added, and then the mixture
refluxed for a longer time period than was necessary for the
synthesis of Cl-Rubbn. [Ru{(NO2)3tpy}Cl3] was prepared in a
similar manner to that previously reported for [Ru(tpy)Cl3],
32
and upon addition of 4,40-dimethyl-2,20-bipyridine yielded
[Ru{(NO2)3tpy}(Me2bpy)Cl]Cl in good yield. The synthesis of the
new chlorido-containing dinuclear complexes Cl-RubbnNO2 and
Cl-RubbNnNO2 were achieved using similar procedures.
Cytotoxicity
The in vitro cytotoxicities of the ruthenium complexes and the
control platinum complexes cisplatin and carboplatin were
determined against the MCF-7 and MDA-MB-231 breast cancer
cell lines, and the results are summarised in Table 1. Cisplatin
showed moderate cytotoxicity against both cell lines, while
carboplatin was essentially inactive. Although IC50 values
reported for cisplatin against MCF-7 cells can vary consider-
ably, the results obtained for both control platinum complexes
against both cell lines are consistent with previous studies.29,33–35
The dinuclear ruthenium complexes Cl-Rubbn, for n = 10, 12 and
14 were more active than cisplatin against both cell lines. Inter-
estingly, Cl-Rubb12 was the most active, with the ruthenium
complexes having the shortest linking chain (Cl-Rubb7) and long-
est linking chain (Cl-Rubb16) being the least active. Addition of
nitro substituents onto the tpy rings of Cl-Rubb12 and Cl-Rubb16
decreased the activity of the ruthenium complexes, particularly in
the case of the highly active Cl-Rubb12. The replacement of two
methylene groups by two amine groups in the ligand bridge for
Cl-Rubb7 (giving Cl-RubbN7) and Cl-Rubb16 (Cl-RubbN16) decreased
the activity of the former but had no effect on the latter complex
that contained the longer linking chain. However, it was also noted
that the replacement of the Me2bpy ligand in [Ru{(NO2)3tpy}-
(Me2bpy)Cl]
+ by the bbN16 ligand to form the mononuclear
complex Cl-RubbN16NO2-mono did significantly increase the
activity in both cancer cell lines. In the one example examined,
the combination of amine groups in the linking ligand and nitro
substituents on the tpy ligands for Cl-RubbN16NO2 had little
Scheme 1
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effect on the cytotoxicity with the MCF-7 cells but decreased the
activity against the MDA-MB-231 cell line.
Aquation and GMP binding
Previous studies with mononuclear ruthenium(II) complexes
that contain a chlorido ligand have shown that the first step
in the binding to GMP, a simple model for DNA, is aquation.
Consistent with previous studies,30 aquation of [Ru(tpy)(Me2bpy)Cl]
+
was found to be relatively fast, with 50% of the ruthenium complex
being converted to the corresponding aqua form in approximately
60 minutes. Similarly, 50% aquation of each ruthenium centre in
the dinuclear complexes Cl-Rubbn and Cl-RubbNn was shown by
1H NMR spectroscopy to occur in approximately 120 minutes
(see Fig. 3). The aquation then proceeds to equilibrium, where
approximately 90% of the ruthenium complex exists in the aqua
form. The inclusion of amine groups into the linking ligand had no
significant effect on the rate or equilibrium position of aquation.
Fig. 4 shows the 1HNMR spectrum of Cl-RubbN16 as a function
of time after dissolution in D2O and the addition of 2 equivalents
of GMP. After 120 minutes, the spectrum of the Cl-RubbN16 is
essentially identical to that in the absence of GMP, as shown in
Fig. 3, with approximately 50% of the dinuclear complex aquated
but with no covalent binding to GMP observed. As evidenced by
the increasing intensity of the resonance at 5.36 ppm, assigned to
the sugar H10 of GMP bound to a ruthenium centre, the aquated
form of Cl-RubbN16 slowly reacts with GMP, reaching an equili-
brium of approximately 33% bound in 24 hours. Similar results
were obtained with the Cl-Rubbn complexes (results not shown).
Fig. 5 shows the 1H NMR spectrum of [Ru{(NO2)3tpy}-
(Me2bpy)Cl]
+ at various time points after the ruthenium complex
Scheme 2
Scheme 3
Table 1 The IC50 values of the metal complexes against the MCF-7 and
MDA-MB-231 breast cancer cell lines, defined as the concentration (mM) of
the complex required to inhibit cell growth by 50%
Metal complex
IC50 (mM)
MCF-7 MDA-MB-231
Cisplatin 34  2 31  3
Carboplatin 273  7 451  8
Cl-Rubb7 29  4 24  5
Cl-Rubb10 8  3 14  3
Cl-Rubb12 8  4 9  4
Cl-Rubb14 7  4 13  1
Cl-Rubb16 27  5 24  6
[Ru{(NO2)3tpy}(Me2bpy)Cl]
+ 48  4 105  7
Cl-RubbN7 68  3 35  4
Cl-RubbN16 27  2 31  4
Cl-Rubb12NO2 42  5 35  4
Cl-Rubb16NO2 36  2 32  2
Cl-RubbN16NO2 31  2 36  2
Cl-RubbN16NO2-mono 27  2 26  2
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was dissolved in D2O. Unlike the corresponding non-nitrated
complex [Ru(tpy)(Me2bpy)Cl]
+, where 495% of the ruthenium
complex was converted into the aqua form well within 24 hours,
60% of the [Ru{(NO2)3tpy}(Me2bpy)Cl]
+ remained unchanged
Fig. 3 Aromatic region of the 1H NMR spectrum of Cl-RubbN16 in D2O as a function of time, after 5 minutes (A), 120 minutes (B) and 27 hours (C).
The asterisk indicates the decrease in the H6-Me2bpy resonances of the Cl-RubbN16 complex, while the arrow shows the increase in the H6-Me2bpy
resonances from the D2O–RubbN16 complex.
Fig. 4 Aromatic region of the 1H NMR spectrum of the Cl-RubbN16 + GMP in D2O as a function of time, after 10 minutes (A), 120 minutes (B),
450 minutes (C), 25 hours (D) and 76 hours (E). The asterisk indicates the decrease in H6-Me2bpy resonances of the Cl-RubbN16 complex, while the
arrows shows the increase of the peak for the H6-Me2bpy protons of the GMP bound ruthenium complex (8.76 ppm) and the sugar H10 of the bound
GMP (5.36 ppm).
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after 24 hours. This indicates that the incorporation of the nitro
substituent on the tpy ligand significantly slowed the aquation
reaction. Even after 216 hours, 25% of the original [Ru{(NO2)3tpy}-
(Me2bpy)Cl]
+ remained in the chlorido form. Interestingly how-
ever, 10% of the [Ru{(NO2)3tpy}(Me2bpy)Cl]
+ was rapidly converted
into another form after being dissolved. This new complex then
appeared to slowly aquate. Based upon the observations of
Fallahpour et al.,36 it is proposed that one of the three nitro
substituents on the tpy ligand is reduced to an amine. This new
‘‘(NO2)2(NH2)-tpy’’ complex then slowly aquates.
Cyclic voltammetry of [Ru{(NO2)3tpy}(Me2bpy)Cl]
+
Electrochemical measurements were carried out on the
[Ru{(NO2)3tpy}(Me2bpy)Cl]
+ and [Ru(tpy)(Me2bpy)Cl]
+ complexes
to assess the electronic effect of the nitro substituents on the
ruthenium centre, and the electrode potentials are listed in
Table 2.
The electrochemical response of the [Ru(tpy)(Me2bpy)Cl]
+
complex as a hexafluorophosphate salt has previously been
investigated;37 the results here are consistent with that report:
two ligand-based reductions are observed in the cathodic
region (tpy/tpy followed by Me2bpy/Me2bpy
), while the ano-
dic region shows a reversible Ru(III/II) peak at +0.90 V. In the
present case, an irreversible peak is also seen at +1.28 V,
corresponding to oxidation of the chloride counter-ion. The
[Ru{(NO2)3tpy}(Me2bpy)Cl]
+ complex shows several important
changes compared to the non-nitrated parent complex. Three
closely-spaced reductions appear at low potentials in the catho-
dic region (0.4 to 0.7 V), followed by further irreversible
peaks at more negative potentials. Previous work on the electro-
chemical behaviour of nitrated bipyridines and their platinum
complexes has shown analogous cathodic behaviour: for example
[Pt{4,40-(NO2)2bpy}Cl2] displayed two closely-spaced reductions, and
the LUMOs for that complex were shown to be localised largely on
the ‘‘NO2-py’’ units.
38 Further reduction of the complex occurred at
1.05 V,39 very close to the potential of 1.06 V observed for the
first reduction (bpy/bpy) of the non-nitrated complex [Pt(bpy)Cl2]
under the same conditions.38 Based on these observations, the first
three cathodic peaks for [Ru{(NO2)3tpy}(Me2bpy)Cl]Cl are assigned
here to reductions involving the NO2-py moieties. The next two
peaks are assigned to further reduction of the (NO2)3tpy ligand and
reduction of the Me2bpy ligand, probably in that order.
Most importantly, the nitro substituents are observed to
exert a strong effect on the ruthenium centre, as the anodic
Fig. 5 Aromatic region of the 1H NMR spectrum of [Ru{(NO2)3tpy}(Me2bpy)Cl]
+ in CD3OD (A) and in D2O as a function of time, after 30 minutes (B),
4 hours (C) and 24 hours (D). NO2–Cl indicates the non-aquated complex {H30 and H50 of (NO2)3tpy} and NO2–D2O represents the aquated form, while
NH2–Cl {H3 and H300 of (NO2)3tpy} and NH2–D2O represent the putative ‘‘(NO2)2(NH2)-tpy’’ complexes.
Table 2 Electrode potentials for [Ru(L)(Me2bpy)Cl]Cl in acetonitrile
(in V vs. Ag/AgCl; working electrode = glassy carbon)
Processa L = tpy L = (NO2)3tpy
Oxidation Ea 0.94
b 1.24 (sh)
1.28 1.33
Reduction Ec 1.36 0.40 (sh)
1.54 0.52 (sh)
0.66
1.17 (sh)
1.45
a All peaks irreversible unless otherwise stated; potentials are given for
forward peaks; anodic (Ea) for oxidations and cathodic (Ec) for reduc-
tions. b Reversible; DEp = 0.90 V.
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peak corresponding to the Ru(III/II) couple is shifted positively
by at least 300 mV, to the point where it coincides with
oxidation of the chloride counter-ion (and is irreversible). This
large positive shift indicates that the nitro substituents cause a
significant decrease in the electron density on the ruthenium
centre, making oxidation to Ru(III) more difficult.
Discussion
The results of this study show that the dinuclear ruthenium(II)
complexes Cl-Rubbn have potential as drugs against breast
cancer. The most active complex, Cl-Rubb12, was almost four-
times more active than cisplatin. Furthermore, Cl-Rubb12 is more
active than the mononuclear [Ru(apy)(tpy)Cl]+ and dinuclear
[{Ru(bpy)2Cl}2{m-BL}]
2+ complexes previously reported by other
groups,28,29 and of similar activity to the most active dinuclear
ruthenium–arene complex linked by a bis(pyridinone)alkane
chain reported by Mendoza-Ferri et al.27 Interestingly, the
Cl-Rubbn complexes with the shortest (Cl-Rubb7) or the longest
linking chain (Cl-Rubb16) were the least active against both
breast cancer cell lines. Insertion of three nitro substituents
onto the tpy ligand of Cl-Rubb12 significantly decreased the
activity against both breast cancer cell lines. Incorporation of
amine groups into the linking bridging ligand of Cl-Rubb7
decreased the activity, whereas it had little effect on the activity
of Cl-Rubb16.
In previous studies with chlorido-containing dinuclear
ruthenium(II) complexes,27,28,30,40 the cytotoxicity has always
increased as the number of methylene groups in the flexible
alkane chain increased. Interestingly, in the present study the
Cl-Rubb16 complex was the least active of the Cl-Rubbn com-
plexes. The decreased activities of Cl-Rubb7 and Cl-Rubb16,
compared to Cl-Rubb12 suggest two competing factors govern
the anticancer activity. While it is yet to be confirmed, it is
assumed that the major mechanism of anticancer activity is
related to DNA binding, analogous to the corresponding dinuclear
platinum complexes. Increasing the number of methylene groups
in the linking chain should increase the lipophilicity of the
dinuclear complex, and hence the ease with which it can pass
through the cellular membrane. While aquation is the necessary
first step in DNA binding, as determined by the GMP binding
experiments, all the Cl-Rubbn complexes exhibited similar rates
of aquation and percentage of the aqua form at equilibrium.
Consequently, the relative cytotoxicity results could imply that
the range of possible DNA cross-linked adducts formed have
significantly different biological outcomes, and/or the anticancer
activity is controlled by both covalent and reversible binding to
DNA. For the corresponding inert Rubbn complexes, the DNA
binding affinity decreases with increasing methylene groups in
the linking chain.41 Furthermore, based purely upon polycation
condensation of polyanionic DNA, it would also be expected that
the cytotoxicity of the Cl-Rubbn complexes would decrease with
increasing chain length.
The inclusion of three nitro substituents on the tpy ligand
significantly increased the IC50 value for the more cytotoxic
Cl-Rubb12 but had a relatively small effect with the less cyto-
toxic Cl-Rubb16. It was determined that the [Ru{(NO2)3tpy}-
(Me2bpy)Cl]
+ complex aquated significantly more slowly than
the non-nitrated parent complex [Ru(tpy)(Me2bpy)Cl]
+. This
observation is consistent with the results from the cyclic
voltammetry study, from which it was concluded that there
was a significant reduction in the electron density on the
ruthenium centre for the trinitrated complex, compared to
the non-nitrated parent complex. The reduced electron density
on the ruthenium centre of [Ru{(NO2)3tpy}(Me2bpy)Cl]
+ would
increase the energy barrier for the removal of the chlorido
ligand from the metal centre, thereby decreasing the rate of
the aquation reaction. Aquation was shown to be the first step
in the coordination of the ruthenium complexes with DNA.
Consequently, the Cl-RubbnNO2 complexes would not form as
many covalent adducts with DNA over the time period of the
cytotoxicity assays, compared to their non-nitrated parent com-
plexes. This suggests that the observed cytotoxicity of the
Cl-RubbnNO2 complexes would largely be due to their reversible,
non-covalent, binding to DNA. Furthermore, it is reasonable to
expect that the chlorido form of the complex would more easily
cross a cellular membrane than the more highly positively-
charged aquated species. Based upon these assumptions, it
could be tentatively concluded that the activity of Cl-Rubb16
was predominantly due to reversible binding to DNA, while the
activity of Cl-Rubb12 was due to a combination of covalent and
reversible binding to DNA.
Although the inclusion of one or more secondary amines
into the bridging ligand of multinuclear platinum complexes
significantly increases their cytotoxicity,2 the incorporation of
amine groups into the ligand bridge of Cl-Rubbn did not
increase the cytotoxicity. For the multinuclear platinum com-
plexes, incorporation of an amine group or an inert am(m)-
ineplatinum(II) centre into the bridge enhances cellular accumu-
lation and increases the affinity for DNA.2,14,42 The corresponding
inert Rubbn dinuclear ruthenium complexes (that do not contain
labile chlorido ligands) enter L1210 murine leukaemia cells by
passive diffusion, with a minor contribution from protein-
mediated active transport.41 Consequently, incorporation of
amine groups into the ligand bridge could decrease the cellular
uptake of the Cl-Rubbn complexes, and thereby result in the
observed lower activity for Cl-RubbN7 relative to Cl-Rubb7. How-
ever, it was also noted that Cl-RubbN16 was equally as active
(albeit weakly) as Cl-Rubb16. This could suggest that the inclusion
of an amine in the bridging ligand of a Cl-Rubbn complex does
increase the reversible binding affinity for DNA, thereby compen-
sating for the lower cellular uptake.
Conclusions
In conclusion, the results of this study support the idea of devel-
oping a new class of anticancer agent by transferring from plati-
num to ruthenium the concept of gaining advantages in efficacy
through the use of multinuclear complexes, as proposed by
Mendoza-Ferri et al.27 Dinuclear ruthenium complexes – containing
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a single chlorido ligand on each metal centre – were synthesised
and found to be significantly more active than cisplatin against two
breast cancer cell lines. The anticancer activity appears to be due to
a combination of covalent and reversible binding with DNA. The
IC50 results indicated that the Cl-Rubb12 complex was the most
active of the dinuclear complexes. The superior activity of
Cl-Rubb12 might be due to the best compromise between
lipophilicity (for cellular uptake) and the cytotoxic effects of
the covalent adducts formed with DNA. Given the vast array of
ligands that can be utilised for the Cl-Rubbn complexes, it
should be possible to optimise cellular uptake and the kinetics
of DNA binding, and thereby produce dinuclear ruthenium(II)
complexes with significant clinical potential.
Experimental
Physical measurements
1D and 2D 1H NMR spectra were recorded on a Varian Advance
400 MHz spectrometer at room temperature in D2O {99.9%,
Cambridge Isotope Laboratories (CIL)}, CDCl3 (99.8%, CIL), or
CD3CN (499.8%, Aldrich). Microanalyses were performed by
the Microanalytical Unit, Research School of Chemistry,
Australian National University, Canberra.
Materials and methods
4,40-Dimethyl-2,2 0-bipyridine (Me2bpy), 2,20:60,200-terpyridine
(tpy), sodium borohydride, phosphorus trichloride, 1,3-diamino-
propane, 1,12-diaminopropane, guanosine 50-monophosphate dis-
odium salt (GMP), ammonium hexafluorophosphate (NH4PF6),
potassium hexafluorophosphate (KPF6) and Amberlite
s IRA-400
(chloride form) anion-exchange resin were purchased from Aldrich
and used as supplied; Sephadexs LH-20 was obtained from GE
Health Care Bioscience, RuCl33H2O was obtained from American
Elements, SeO2 was obtained from Ajax Chemicals. The syntheses
of ligands bbn (n = 7, 10, 12, 14 and 16)
31 and [Ru(tpy)Cl3]
32 were
performed according to reported literature methods.
Cyclic voltammetry
Cyclic voltammetry was carried out using an eDAQ EA161
potentiostat operated via an eDAQ ED401 e-corder. A glassy
carbon working electrode, platinum wire counter electrode and
Ag/AgCl reference electrode were used. HPLC grade acetonitrile was
used as solvent and the supporting electrolyte was 0.1 mol L1
tetra-n-butyl ammonium hexafluorophosphate (Aldrich).
Cytotoxicity assays
Cytotoxicity data was obtained using the mitochondrial-
dependent reduction of 3-(3,4-dimethylthiazol-2yl)-5-diphenyl
tetrazolium bromide (MTT) to formazan as described by Guh
et al.43 Metal complex solutions, including the control platinum
complexes cisplatin and carboplatin, were made to the required
concentrations in warmMilli-Q water. Growth inhibition assays
were carried out over a 72 h continuous exposure period.
Synthesis of ligands
Trinitro-terpyridine
2,20:60,200-Terpyridine trioxide. A solution of 2,20:60,200-
terpyridine (4.0 g, 17.1 mmol) in glacial acetic acid (21 mL)
and 30% hydrogen peroxide (14 mL) was heated for 2 h at 80 1C
after addition of further hydrogen peroxide (14 mL) the tem-
perature was raised to 90 1C and maintained for 18 h. The
mixture was then poured into acetone (200 mL). After standing
for 4–6 h, the precipitate was filtered and washed with acetone
(2 40 mL) to obtain 4.2 g of pure product (yield 88%). 1H NMR
(400 MHz, CDCl3): d 8.35 (t, J = 9.3 Hz, 2H); 7.81 (d, J = 6.9 Hz,
2H); 7.77 (t, J = 10.4 Hz, 2H); 7.45 (t, J = 14.5 Hz, 1H);
7.36 (m, 4H).
4,40,400-Trinitro-2,2 0:60,200-terpyridine trioxide. Fuming nitric
acid (90%, 7.2 mL) was added slowly to a cooled mixture of
2,20:60,200-terpyridine trioxide (4.2 g, 15.1 mmol), conc. sulfuric
acid (15 mL) and fuming sulfuric acid (30%, 3.6 mL) at 0–5 1C.
The mixture was then stirred at 100 1C for 1 h and at 120 1C for
4 h. The contents of the flask were then poured into ice water
and filtered. The precipitate, after washing first with sodium
bicarbonate solution (40 mL) and then with water (40 mL), was
dried and crystallised from 50% aqueous pyridine (50 mL) to
yield 1.3 g of a light yellow coloured product (yield 21%).
1H NMR (400 MHz, CDCl3): d 8.66 (s, 2H); 8.55 (d, J = 3.0 Hz,
2H); 8.39 (d, J = 7.4 Hz, 2H); 8.25 (dd, J = 2.9 Hz, 3.2 Hz, 2H).
4,40,400-Trinitro-2,2 0:60,200-terpyridine. A mixture of 4,40,400-
trinitro-2,20:60,200-terpyridine trioxide (1.3 g) and phosphorus
trichloride (15 mL) was refluxed for 18 h under an Ar atmo-
sphere, and the hot solution was then poured on ice and made
alkaline with 40% ammonium hydroxide solution. The preci-
pitate was filtered, dried under vacuum, and crystallised from
benzene to obtain 0.64 g of the pure product (yield 56%).
1H NMR (400 MHz, CDCl3): d 9.30 (s, 2H); 9.28 (d, J = 2.0 Hz,
2H); 9.08 (d, J = 5.2 Hz, 2H); 8.18 (dd, J = 2.0 Hz, 1.9 Hz, 2H).
bbNn ligands
4-Formyl-40-methyl-2,20-bipyridine. 4,40-Dimethyl 2,20-bipyridine
(2.0 g, 10.8 mmol) and SeO2 (1.8 g, 16.7 mmol) were refluxed in
1,4-dioxane (45 mL) under a N2 atmosphere for 24 h. The solution
was filtered while hot to remove the solid selenium and the filtrate
allowed to stand at room temperature for 1 h and then evaporated
to obtain a pale pink powder. This crude product was redissolved
in ethyl acetate (150 mL), the undissolved solid was removed by
filtration and the filtrate was evaporated to obtain pale yellow
solid. The crude product was dissolved in minimal volume of
DCM and impregnated with silica gel (230–400 mesh, 5 g) the
impregnated mixture was then loaded on a silica gel column
(230–400 mesh; 3 cm diam.  15 cm), the unreacted Me2bpy was
eluted with 5% (v/v) ethyl acetate in n-hexane and the product
was eluted using 20–30% (v/v) ethyl acetate in n-hexane. The
purity of each fraction was monitored by TLC, using 30% (v/v)
ethyl acetate in n-hexane as the mobile phase. The purest
fractions were combined and the solvent was evaporated in vacuo
to obtain white solid. A final recrystallisation with n-pentane
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gave 0.82 g of the pure product as a white powder (yield 38%).
1H NMR (400 MHz, CDCl3): d 10.17 (s, 1H); 8.89 (d, J = 5.1 Hz,
1H); 8.85 (s, 1H); 8.57 (d, J = 4.9 Hz, 1H); 8.28 (s, 1H); 7.72
(d, J = 5.0 Hz, 1H); 7.20 (d, J = 4.2 Hz, 1H); 2.46 (s, 3H).
bbN7. A mixture of 4-formyl-40-methyl-2,2 0-bipyridine (0.74 g
3.76 mmol) and the 1,3-diaminopropane (0.16 mL, 1.88 mmol)
was stirred in methanol (50 mL) at room temperature under N2
atmosphere for 4 h. Sodium borohydride (0.57 g, 15.07 mmol)
was then added to the reaction mixture and stirred at 65 1C for
1–2 h. The solvent was evaporated from the reaction mixture
and water (10 mL) added to the crude residue. The organic
component was extracted with dichloromethane (3  50 mL),
and the organic phase was then washed with water (20 mL) and
brine (20 mL). After removing the solvent, the crude residue
was purified by column chromatography using silica gel, the
unreacted starting material and other impurities were eluted
with 1–2% (v/v) MeOH in DCM and the bbN7 was eluted with
5–8% (v/v) MeOH and 0.1% (v/v) triethylamine in DCM. Yield:
0.38 g, 23%. 1H NMR (400 MHz, CDCl3): d 8.59 (d, J = 6.2 Hz,
2H); 8.53 (d, J = 7.9 Hz, 2H); 8.32 (s, 2H); 8.22 (s, 2H); 7.30
(bs, 2H); 7.13 (d, J = 3.9 Hz, 2H); 3.89 (s, 4H); 2.74 (t, J = 10.9 Hz,
4H); 2.44 (s, 6H); 1.66–1.52 (m, 2H).
bbN16. This compound was prepared analogously to the
above method from 4-formyl-40-methyl-2,2 0-bipyridine (0.81 g
4.10 mmol) and 1,12-diaminopropane (0.41 g, 2.05 mmol).
Yield: 0.56 g, 24%. 1H NMR (400 MHz, CDCl3): d 8.61 (d, J =
5.0 Hz, 2H); 8.52 (d, J = 4.9 Hz, 2H); 8.30 (s, 2H); 8.21 (s, 2H);
7.36 (bs, 2H); 7.12 (d, J = 5.1 Hz, 2H); 3.90 (s, 4H); 2.63 (t, J =
14.3 Hz, 4H); 2.42 (s, 6H); 1.33–1.21 (m, 20H).
Synthesis of metal complexes
[{Ru(tpy)Cl}2{m-bbn}]
2+ (Cl-Rubbn). The ruthenium(II) com-
plexes Cl-Rubbn were synthesised using a slight modification
of methods previously described.30
[Ru{(NO2)3tpy}Cl3]. 4,40,400-Trinitro-2,20:60,200-terpyridine (0.44 g,
1.7 mmol) was stirred in absolute ethanol (220 mL) with gentle
heating until dissolution. RuCl33H2O (0.63 g, 1.7 mmol) was
added and the solution refluxed for 3 h with stirring under
nitrogen atmosphere. After the mixture was cooled to room
temperature, the violet brown precipitate was filtered, washed
with excess of ethanol and ether, and dried under vacuum to yield
0.58 g of the product (yield 59%). 1H NMR (400 MHz, DMSO-d6):
d 9.91 (s, 2H); 9.73 (d, J = 2.5 Hz, 2H); 9.70 (d, J = 6.3 Hz, 2H); 8.30
(dd, J = 2.5 Hz, 2.4 Hz, 2H). 13C NMR (DMSO-d6): d 160.0, 158.1,
157.3, 154.2, 153.2, 120.8, 117.9, 117.5, 56.4, 19.0.
[Ru{(NO2)3tpy}(Me2bpy)Cl]Cl. A solution of [Ru{(NO2)3tpy}Cl3]
(0.10 g, 0.17 mmol) and Me2bpy (0.032 g, 0.17 mmol) in EtOH/
H2O (4 : 1; 20 mL) was refluxed under an N2 atmosphere for 5 h.
After cooling, the solvent mixture was evaporated to approxi-
mately half of the original volume and saturated aqueous
NH4PF6 was added slowly to precipitate a dark violet-purple
material, which was filtered and washed with ethanol (2 15 mL)
followed by diethyl ether (2  15 mL). The crude product was
dissolved in a minimum amount of acetone and loaded onto a
column of Sephadex LH-20 (2 cm diam.  30 cm), and using
acetone as the eluent, the major first band was collected and
acetone was evaporated to obtain [Ru{(NO2)3tpy}(Me2bpy)Cl]PF6
complex as a dark violet-brown material and was crystallised
using acetonitrile–toluene. Anal. calcd for [Ru{(NO2)3tpy}-
(Me2bpy)Cl]PF6: C, 38.9%; H, 2.42%; N, 13.4%. Found: C,
39.0%; H, 2.22%; N, 13.2%. 1H NMR (400 MHz, CD3CN):
d 9.90 (d, J = 5.4 Hz, 1H); 9.57 (s, 2H); 9.35 (t, J = 2.5 Hz, 2H);
8.56 (s, 1H); 8.23 (s, 1H); 8.07–8.05 (m, 4H); 7.92 (d, J = 5.7 Hz,
1H); 6.88 (d, J = 5.9 Hz, 1H); 6.80 (d, J = 6.0 Hz, 1H); 2.82 (s, 3H);
2.34 (s, 3H). 13C NMR (CD3CN): d 160.8, 159.9, 157.7, 155.6,
154.9, 154.4, 152.35, 152.28, 152.20, 151.3, 150.9, 129.4, 128.2,
125.6, 125.4, 122.2, 118.9, 118.7, 21.4 and 20.8.
The chloride salt was obtained by stirring the PF6
 salt in
water with Amberlite IRA-400 (chloride form) anion-exchange
resin. The resin was removed by filtration, and the dark violet-
brown solution was freeze-dried to obtain a fluffy dark violet-
brown [Ru{(NO2)3tpy}(bpy)Cl]Cl. Yield: 65 mg, 51%.
[{Ru{(NO2)3tpy}(Cl)}2(m-bbn)]Cl2. The syntheses of [{Ru{(NO2)3tpy}-
(Cl)}2(m-bbn)]Cl2 (n = 12, 16) complexes were adapted from
literature methods.30,32 [Ru{(NO2)3tpy}Cl3] (70 mg, 0.12 mmol)
was dissolved in EtOH/H2O (4 : 1; 15 mL), the appropriate bbn
ligand (0.06 mmol) added and the mixture was refluxed under
an N2 atmosphere for 5–6 h. After cooling, the solvent from the
reaction mixture was evaporated to approximately half of the
original volume and then cooled, after which a saturated
aqueous NH4PF6 solution was slowly added until no further
precipitation occurred. The dark violet-purple precipitate was
then filtered and washed with ethanol (2  20 mL) followed by
diethyl ether (2  20 mL). The crude product was dissolved in a
minimum amount of acetone and loaded onto a column of
Sephadex LH-20 (2 cm diam.  30 cm); on elution with acetone
the major first band collected. The pure [{Ru{(NO2)3tpy}Cl}2-
(m-bbn)](PF6)2 complex was isolated as dark violet-purple
material.
[{Ru{(NO2)3tpy}(Cl)}2(m-bb16)](PF6)2. Anal. calcd for
[{Ru(NO2terpy)(Cl)}2(m-bb16)](PF6)2C3H6O: C, 44.4%; H,
3.78%; N, 11.7%. Found: C, 44.3%; H, 3.67%; N, 11.3%.
1H NMR (400 MHz, CD3CN): d 9.91 (d, J = 5.8 Hz, 2H); 9.56
(s, 4H); 9.37–9.33 (m, 4H); 8.56 (dd, J = 3.8 Hz, 3.5 Hz, 2H); 8.24
(dd, J = 3.3 Hz, 4.7 Hz, 2H); 8.08–8.06 (m, 8H); 7.93–7.90
(m, 2H); 6.88 (m, 2H); 6.83–6.79 (m, 2H); 3.08–3.07 (m, 2H);
2.82 (s, 3H); 2.61–2.60 (m, 2H); 2.34 (s, 3H); 1.60–1.10 (m, 28H).
13C NMR (CD3CN): d 160.8, 159.9, 157.90, 157.85, 156.7, 155.8,
154.96, 154.92, 154.5, 152.4, 152.33, 152.29, 152.25, 151.3,
150.9, 129.4, 128.7, 128.2, 127.5, 125.7, 125.4, 124.9, 124.7,
122.2, 119.0, 118.7, 36.0, 35.4, 31.1, 30.7, 30.6, 30.46, 30.42,
30.39, 30.30, 30.1, 29.96, 29.92, 29.6, 21.5 and 20.9.
[{Ru{(NO2)3tpy}(Cl)}2(m-bb12)](PF6)2. Anal. calcd for
[{Ru{(NO2)3tpy}Cl}2(m-bb12)](PF6)2: C, 42.6%; H, 3.24%; N,
12.4%. Found: C, 42.8%; H, 3.33%; N, 12.2%. 1H NMR (400 MHz,
CD3CN): d 9.91 (d, J = 5.3 Hz, 2H); 9.56 (s, 4H); 9.36–9.32 (m, 4H);
8.55 (dd, J = 5.8 Hz, 6.6 Hz, 2H); 8.23 (dd, J = 5.4 Hz, 7.0 Hz, 2H);
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8.07 (m, 8H); 7.92–7.89 (m, 2H); 6.88 (d, J = 5.6 Hz, 2H); 6.81
(m, 2H); 3.07–3.06 (m, 2H); 2.81 (s, 3H); 2.60–2.59 (m, 2H); 2.34
(s, 3H); 1.61–1.08 (m, 20H). 13C NMR (CD3CN): d 160.8, 159.9,
157.8, 156.6, 155.7, 154.95, 154.90, 154.4, 152.4, 152.33, 152.29,
152.24, 151.3, 150.9, 129.4, 128.7, 128.2, 127.5, 125.6, 125.4,
124.9, 124.7, 122.2, 118.9, 118.7, 36.0, 35.3, 31.1, 30.76, 30.73,
30.4, 30.3, 30.19, 30.13, 30.09, 29.99, 29.96, 29.89, 29.72, 29.66,
21.4 and 20.9.
The chloride salts were obtained by stirring the PF6 salt in
water using Amberlite IRA-400 (chloride form) anion-exchange
resin. The resin was removed by filtration, and the solution was
freeze-dried to obtain a fluffy dark violet-purple powder of pure
[{Ru(NO2terpy)(Cl)}2(m-bbn)]Cl2 in 30–35% yield.
[{Ru(tpy)Cl}2(m-bbH2Nn)]Cl4. To the bbN7 ligand (53 mg,
0.122 mmol) dissolved in EtOH/H2O (4 : 1; 15 mL), solid
[Ru(tpy)Cl3] (108 mg, 0.245 mmol) was added at 60 1C and
the reaction mixture was refluxed under an N2 atmosphere for
5–6 h. After cooling, half of the solvent was evaporated from the
reaction mixture and saturated aqueous NH4PF6 was added to
obtain the PF6
 salt as a dark purple-brown material, which was
filtered and washed with ethanol (2  20 mL) followed by
diethyl ether (2  20 mL). The crude product was dissolved in a
minimum amount of acetone and loaded onto a column of
Sephadex LH-20 (2 cm diam. 30 cm); and eluted with acetone,
the major first band (dark purple coloured) was collected, the
acetone evaporated to obtain [{Ru(tpy)Cl}2(m-bbH2Nn)]Cl4
complex as a dark purple-brown material.
[{Ru(tpy)Cl}2(m-bbH2N7)](PF6)2Cl2. Anal. calcd for [{Ru(tpy)Cl}2-
(m-bbH2N7)](PF6)2Cl2: C, 44.4%; H, 3.53%; N, 10.9%. Found: C,
44.6%; H, 3.75%; N, 10.6%. 1H NMR (400 MHz, CD3CN): d 10.16
(dd, J = 5.0 Hz, 5.4 Hz, 1H); 10.00 (d, J = 5.7 Hz, 1H); 8.50–8.46
(m, 4H); 8.37–8.29 (m, 6H); 8.12–8.05 (m, 4H); 7.82 (m, 6H); 7.66–
7.62 (m, 4H); 7.24–7.6 (m, 6H); 7.05 (d, J = 6.3 Hz, 1H); 6.80
(bs, Hz, 1H); 4.50 (bs, 2H); 4.07 (bs, 2H); 3.10–3.03 (m, 2H); 2.93–
2.87 (m, 2H); 2.68 (s, 3H); 2.33 (s, 3H); 1.70–1.64 (m, 2H). 13C NMR
(CD3CN): d 159.5, 158.8, 158.6, 153.5, 153.1, 152.6, 152.2, 149.8,
149.1, 137.9, 134.6, 128.9, 128.1, 127.2, 125.4, 124.4, 123.4, 51.3,
46.0, 21.5 and 20.8.
[{Ru(tpy)Cl}2(m-bbH2N16)](PF6)2Cl23H2O. Anal. calcd for
[{Ru(tpy)Cl}2(m-bbH2N16)](PF6)2Cl23H2O: C, 46.0%; H, 4.57%;
N, 9.8%. Found: C, 45.6%; H, 4.28%; N, 9.4%. 1H NMR
(400 MHz, CD3CN): d 10.27 (d, J = 5.2 Hz, 1H); 10.03 (d, J =
5.6 Hz, 1H); 8.59 (bs, 1H); 8.50 (dd, J = 1.1 Hz, 1.8 Hz, 4H); 8.43
(bs, 1H); 8.39 (dd, J = 1.7 Hz, 2.6 Hz, 4H); 8.30 (bs, 1H); 8.15
(bs, 1H); 8.11 (t, J = 16.2 Hz, 2H); 7.98–7.95 (m, 1H); 7.92–7.87
(m, 4H); 7.85 (dd, J = 2.5 Hz, 2.3 Hz, 1H); 7.67–7.63 (m, 4H); 7.37
(bs, 1H); 7.31–7.28 (m, 4H); 7.17 (d, J = 5.7 Hz, 1H); 6.95 (d, J =
5.8 Hz, 1H); 6.86 (d, J = 5.2 Hz, 1H); 4.49 (bs, 2H); 4.06 (bs, 2H);
3.23–3.16 (m, 2H); 2.94–2.86 (m, 2H); 2.78 (s, 3H); 2.36 (s, 3H);
1.61–1.20 (m, 20H). 13C NMR (CD3CN): d 160.1, 159.6, 159.5,
158.9, 158.7, 158.4, 157.5, 156.2, 153.6, 153.1, 153.0, 152.9,
152.6, 152.2, 149.9, 149.1, 137.9, 134.7, 134.5, 128.9, 128.2,
128.1, 127.8, 126.8, 125.1, 124.45, 124.42, 124.1, 123.4, 123.3,
51.2, 50.7, 49.5, 49.3, 30.0, 29.9, 29.6, 29.5, 27.3, 27.0, 26.9, 21.4
and 20.9.
The chloride salt was obtained by stirring the PF6
 salt in
water with Amberlite IRA-400 (chloride form) anion-exchange
resin. The resin was removed by filtration, and the solution was
freeze-dried to obtain a fluffy dark purple-brown powder of
[{Ru(tpy)Cl}2(m-bbH2Nn)]Cl4. Yield: 20–25%.
[{Ru{(NO2)3tpy}(Cl)}2(m-bbH2N16)]Cl4. The synthesis of
[{Ru{(NO2)3tpy}(Cl)}2(m-bbH2N16)]Cl4 complex was prepared as
described for [{Ru(tpy)Cl}2(m-bbH2Nn)]Cl4. Typical yieldB20%.
[{Ru{(NO2)3tpy}(Cl)}2(m-bbH2N16)](PF6)2Cl2. Anal. calcd for
[{Ru(NO2tpy)(Cl)}2(m-bbH2N16)](PF6)2Cl21.5C3H6O: C, 41.8%;
H, 3.73%; N, 12.5%. Found: C, 41.7%; H, 3.48%; N, 12.1%.
1H NMR (400 MHz, CD3CN): d 9.92–9.91 (m, 2H); 9.57 (s, 2H);
9.48 (s, 1H); 9.36 (s, 2H); 9.31 (dd, J = 1.6 Hz, 2.1 Hz, 2H); 8.71
(m, 1H); 8.56–8.55 (m, 2H); 8.40–8.37 (m, 1H); 8.26–8.25
(m, 1H); 8.17 (d, J = 2.5 Hz, 1H); 8.07–8.05 (m, 8H); 7.43 (t, J =
10.2 Hz, 1H); 6.97–6.95 (m, 4H); 4.28 (dd, J = 5.8 Hz, 5.0 Hz, 2H);
3.84–3.82 (m, 2H); 2.96–2.95 (m, 2H); 2.82 (s, 3H); 2.79–2.77
(m, 2H); 2.35 (s, 3H); 1.74–1.05 (m, 20H). 13C NMR (CD3CN):
d 160.79, 160.74, 159.8, 159.7, 155.4, 154.9, 154.4, 153.0, 152.2,
151.6, 151.1, 129.5, 128.44, 128.32, 126.9, 125.6, 125.0, 124.3,
122.2, 119.3, 118.9, 118.6, 115.5, 112.8, 51.0, 49.4, 29.8, 29.6,
28.1, 27.2, 21.4, 20.9 and 14.4.
[Ru{(NO2)3tpy}(Cl)(bbH2N16)]Cl3. The mononuclear complex
was prepared using an analogous method to that reported for
[{Ru(tpy)Cl}2(m-bbH2Nn)]Cl4 from [Ru{(NO2)3tpy}Cl3] (50 mg,
0.086 mmol) and the bbN16 ligand (49 mg, 0.086 mmol) to
obtain [Ru{(NO2)3tpy}(Cl)(bbH2N16)]Cl3 as dark violet-brown
solid. Typical yield B24%.
[Ru{(NO2)3tpy}(Cl)(bbH2N16)](PF6)Cl2. Anal. calcd for
[Ru{(NO2)3terpy}(Cl)(bbH2N16)](PF6)Cl20.5C3H6O: C, 47.9%; H,
4.67%; N, 12.5%. Found: C, 47.7%; H, 4.47%; N, 12.6%.
1H NMR (400 MHz, CD3CN): d 9.95 (m, 1H); 9.56 (d, J =
3.4 Hz, 1H); 9.46 (m, 1H); 9.33–9.30 (m, 2H); 8.66 (m, 1H);
8.50–8.41 (m, 2H); 8.33 (m, 1H); 8.26–8.22 (m, 2H); 8.17
(m, 1H); 8.03–7.96 (m, 5H); 7.44–7.41 (m, 2H); 7.27–7.24
(m, 1H); 6.97–6.89 (m, 3H); 4.28–4.26 (m, 2H); 3.76–3.71
(m, 2H); 2.84–2.78 (m, 4H); 2.46–2.39 (m, 3H); 2.34 (s, 3H);
1.65–1.08 (m, 20H). 13C NMR (CD3CN): d 168.0, 161.5, 161.0,
160.0, 159.3, 158.4, 158.1, 157.9, 156.1, 155.1, 154.7, 153.5,
153.3, 153.1, 152.8, 152.5, 152.1, 151.8, 150.1, 129.4, 128.4,
127.6, 127.3, 126.6, 125.6, 123.9, 122.8, 122.5, 122.2, 121.9,
115.8, 113.0, 66.8, 50.1, 49.6, 30.4, 29.8, 28.0, 27.6, 21.5, 20.0
and 14.7.
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